21
Jul
2026
21
Jul
2026
Botulinum toxin treatments are widely used in both medical and aesthetic practice, and nurses can play an important role in supporting safe patient care throughout the treatment journey.
Depending on their role, qualifications, prescribing authority and scope of practice, nurses may be involved in patient assessment, treatment preparation and administration, patient education, aftercare, follow-up and the recognition and escalation of potential complications.
Recent strengthened safety warnings from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) regarding the rare risk of iatrogenic botulism have also highlighted the importance of continued vigilance, robust clinical governance and effective patient education.
For nurses working in aesthetic medicine, understanding the potential risks associated with botulinum toxin and knowing how to respond to concerns is an important part of supporting safe, high-quality patient care.
However, regulatory requirements and professional responsibilities differ between the UK and Ireland. Nurses should always work within their own professional scope of practice and follow the regulatory and legal requirements applicable in the country in which they practise.
Botulinum toxin is a prescription-only medicine used for a range of therapeutic and aesthetic indications.
In aesthetic medicine, botulinum toxin is commonly used to temporarily reduce the appearance of dynamic facial lines by reducing muscle activity. It is also used medically to treat a range of conditions.
While botulinum toxin has an established safety profile when used appropriately, it is a potent neurotoxin and should only be prescribed and administered within the appropriate regulatory and clinical framework.
Different botulinum toxin products have different licensed indications, dosing recommendations and administration requirements. Units are not interchangeable between products, making it essential that healthcare professionals follow the product-specific prescribing information.
Nurses working in aesthetic medicine can play an important role in supporting patient safety throughout the treatment journey, within their professional scope of practice and the regulatory requirements of the jurisdiction in which they practise.
Depending on their role, this may include:
Supporting appropriate patient assessment
Identifying relevant medical history and risk factors
Supporting informed consent and patient education
Administering treatment where appropriately trained, competent and authorised to do so
Providing clear pre- and post-treatment information
Recognising potential complications
Escalating concerns appropriately
Supporting patients who experience adverse events
Maintaining accurate clinical documentation
Contributing to effective clinical governance
The precise responsibilities of an individual nurse will depend on their professional role, qualifications, competence, prescribing authority and local regulatory requirements.
A strong understanding of botulinum toxin treatments and their potential complications can help nurses recognise when a patient's symptoms may require further assessment or urgent medical intervention.
The regulatory environment for aesthetic practice is not identical across the UK and Ireland. Nurses should ensure they understand the rules and professional standards that apply to their own practice.
In the UK, botulinum toxin is a prescription-only medicine. The MHRA has strengthened warnings for botulinum toxin type A products following rare reports of iatrogenic botulism.
The MHRA advises healthcare professionals to be alert to symptoms that may indicate the spread of toxin beyond the intended treatment area and to ensure that patients receive appropriate information about potential symptoms and when to seek medical attention.
The MHRA also states that prescribers should ensure that anyone they direct to administer botulinum toxin is familiar with the relevant prescription and safety information.
For nurses and midwives who are independent prescribers, the Nursing and Midwifery Council (NMC) has specific standards and requirements that apply to prescribing. Since 1 June 2025, NMC-registered independent nurse and midwife prescribers must conduct a face-to-face consultation and appropriate clinical assessment before prescribing medicines for elective non-surgical cosmetic procedures.
Nurses should ensure that their practice complies with the NMC Code, relevant prescribing standards and applicable UK legislation and guidance.
In Ireland, botulinum toxin is also a prescription-only medicine.
The Health Products Regulatory Authority (HPRA) advises that botulinum toxin products should be authorised for use in Ireland or the European Union and obtained through appropriate authorised supply chains.
The HPRA has advised that cosmetic procedures involving botulinum toxin should be carried out by a registered medical doctor or dentist, or by a registered nurse under the direction of a medical doctor or dentist.
Registered nurses working in aesthetic medicine in Ireland should also ensure that their practice is consistent with relevant Nursing and Midwifery Board of Ireland (NMBI) professional standards and guidance, including guidance relating to non-surgical aesthetic and cosmetic procedures.
Nurses should work within their individual scope of practice, competence and professional responsibilities and ensure that appropriate medical oversight and prescribing arrangements are in place.
Appropriate patient assessment is an important part of safe aesthetic practice.
Relevant medical history should be considered before treatment, including any conditions or medications that could affect the suitability of botulinum toxin treatment.
Healthcare professionals should be particularly alert to relevant neurological conditions and a history of swallowing difficulties or aspiration, as these may be relevant to the risk of adverse effects.
Patients should also be assessed in the context of the specific product being prescribed and the proposed treatment area.
A thorough assessment should be documented appropriately, and any concerns should be discussed with the responsible prescriber or appropriate medical professional before treatment proceeds.
In the UK, nurses who are independent prescribers must ensure that they comply with the NMC's requirements for prescribing cosmetic medicines. In Ireland, nurses should follow the relevant NMBI guidance and work within the appropriate medical direction and prescribing framework.
Botulinum toxin products are not interchangeable.
Healthcare professionals should be familiar with the specific product being used, including its:
Licensed indications
Recommended doses
Approved administration sites
Contraindications and warnings
Storage requirements
Product-specific safety information
Clinics should ensure that products are obtained through legitimate and appropriate supply chains and that robust procedures are in place for procurement, storage and stock management.
The use of counterfeit, falsified or unauthorised products can present significant risks to patients.
Good product governance is an essential part of patient safety.
Patients should receive clear and appropriate information about their treatment before they proceed.
This includes understanding the expected effects of treatment as well as potential risks and complications.
Following treatment, patients should know:
What symptoms to expect
Which symptoms may indicate a potential complication
Who to contact if they have concerns
When they should seek urgent medical attention
Clear communication is particularly important because some complications may not become apparent immediately following treatment.
Patients should also understand that botulinum toxin products are prescription medicines and that their use should be based on an appropriate clinical assessment and prescribing process.
One of the most important areas for nurses to understand is the recognition of symptoms that may indicate the effects of botulinum toxin have spread beyond the intended treatment area.
The MHRA advises that symptoms associated with iatrogenic botulism typically develop between four and eight days after treatment but can occur up to four weeks later.
Potential symptoms include:
Difficulty swallowing
Difficulty speaking or slurred speech
Breathing difficulties or shortness of breath
Muscle weakness
Severe drooping of the upper eyelids
Patients should be advised to seek immediate medical attention if they develop symptoms such as difficulty swallowing or breathing following botulinum toxin treatment.
These symptoms require prompt medical assessment and should not be dismissed as routine post-treatment effects.
If a patient contacts a clinic with symptoms that could indicate a serious adverse reaction, the situation should be taken seriously and managed in accordance with the clinic's clinical governance and escalation procedures.
Depending on the symptoms and their severity, this may involve:
Assessing the patient's reported symptoms and their onset within the nurse's scope of practice.
Escalating concerns to the responsible prescriber or appropriate medical professional.
Advising the patient to seek urgent medical attention where clinically appropriate.
Providing relevant information about the treatment and product to support further assessment.
Documenting the patient's symptoms and the actions taken.
Following appropriate adverse event reporting procedures.
Breathing difficulties, significant swallowing problems or rapidly progressing weakness should be treated as potentially serious symptoms requiring urgent medical attention.
Nurses should always work within their professional scope of practice and follow their organisation's escalation and emergency procedures.
Not every post-treatment symptom indicates botulism or a serious adverse reaction. However, healthcare professionals should be alert to symptoms that are unusual, severe, progressive or affecting functions beyond the intended treatment area.
Particular care should be taken where a patient reports:
New or worsening difficulty swallowing
Difficulty breathing
Slurred speech
Generalised muscle weakness
Significant or unusual visual symptoms
Symptoms that are progressively worsening
Where there is concern about a serious adverse reaction, appropriate medical assessment should not be delayed.
Good documentation is an important part of safe aesthetic practice.
Records should accurately reflect relevant aspects of the patient's care, in accordance with applicable professional and regulatory requirements. This may include:
Patient assessment
Medical history and relevant risk factors
Treatment indication
Product used
Batch or lot number where required
Dose administered
Treatment sites
Prescriber details
Information provided to the patient
Any reported adverse events
Actions taken and referrals made
Clinics should also have clear processes for patient follow-up and for managing concerns raised after treatment.
Healthcare professionals should be familiar with the adverse reaction reporting system applicable in their jurisdiction.
In the UK, suspected adverse drug reactions can be reported through the MHRA Yellow Card Scheme.
In Ireland, suspected adverse reactions can be reported through the HPRA's national reporting system.
Reporting suspected adverse reactions helps regulators monitor the safety of medicines and identify emerging safety concerns.
Healthcare professionals should follow current national guidance and their organisation's internal procedures for documenting and escalating adverse events.
Aesthetic medicine continues to evolve, and ongoing education is an important part of maintaining safe practice.
For nurses working with botulinum toxin, relevant education should extend beyond injection technique and include:
Anatomy
Pharmacology
Patient assessment
Contraindications
Complications management
Emergency response
Consent
Professional and ethical considerations
Clinical governance
Regulatory requirements
Nurses should ensure they have the appropriate education, training and competence for the role they undertake and maintain their knowledge through relevant continuing professional development.
Regularly reviewing current safety updates and ensuring that clinical teams understand their responsibilities can help maintain high standards of patient care.
Recent safety updates provide a useful opportunity for aesthetic clinics to review their existing procedures.
Consider asking:
Are our patient assessment processes sufficiently thorough?
Do our consent and patient information materials clearly explain relevant risks and warning signs?
Do patients know who to contact if they have concerns following treatment?
Are our emergency and escalation procedures clear to the whole team?
Are staff confident in recognising potential symptoms of serious adverse reactions?
Are our products sourced through legitimate and appropriate channels?
Are our clinical records and adverse event reporting processes robust?
Are all practitioners working within their professional scope of practice and the regulatory requirements of the country in which they practise?
Regular reviews of these processes can help identify opportunities to strengthen patient safety and clinical governance.
Safe aesthetic practice relies on effective teamwork.
Prescribers, nurses, healthcare professionals and clinic teams all have a role to play in ensuring that patients receive appropriate assessment, treatment and follow-up.
For nurses, this means maintaining awareness of potential complications, recognising when symptoms may require escalation and ensuring patients receive clear and appropriate information.
The recent safety updates are an important reminder that vigilance should continue beyond the treatment room. Patient safety is supported not only by the technical delivery of a treatment, but also by appropriate assessment, product governance, informed consent, clear aftercare advice and effective management of potential complications.
Botulinum toxin remains an established prescription medicine used across both medical and aesthetic settings. However, as with any prescription medicine, its safe use depends on appropriate clinical assessment, product knowledge, professional competence and robust governance.
For nurses working in aesthetic medicine in the UK and Ireland, understanding the potential complications associated with botulinum toxin and knowing when and how to escalate concerns is an important part of supporting safe patient care.
While the regulatory frameworks differ between the UK and Ireland, the principles of working within professional competence, using appropriately authorised products, maintaining clear clinical records, providing appropriate patient information and responding promptly to potential complications remain central to safe practice.
Keeping clinical knowledge up to date, reviewing safety processes and ensuring patients know when to seek help can all contribute to safer outcomes and high standards of professional practice.
Healthcare professionals should always refer to the latest guidance from the relevant regulator and professional body in their jurisdiction, as requirements and guidance may change.
Read it? Loved it? Want to share it?
